BenzingaOctober 13, 2026 at 4:48 AM NY14 Days Ago
Truist Securities Maintains Buy on Nurix Therapeutics, Lowers Price Target to $33
Truist Securities analyst Gregory Renza maintains Nurix Therapeutics (NASDAQ:NRIX) with a Buy and lowers the price target from $34 to $33.
What This Story Means
Claude is explaining the story in plain words…
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site: Benzinga
